MedWatch

Bavarian Nordic maintains guidance for 2021

In its Thursday Q1 report, Bavarian Nordic states that it is maintaining its guidance for 2021. It expects DKK 1.9-2.2bn in revenue and an operating result of DKK 100-250m.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic closed its first quarter with growth on the top line though negative results in operations and on the bottom line have also increased significantly.

The company is advancing in spite of waning sales from the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs